OraSure Technologies Inc. logo

OraSure Technologies Inc.

OSUR | NASDAQ
Chart Builder DCF Calculator
$3.98
+$0.29 (+7.86%)
Sep 22, 2026, 2:42 PM ET · Market open

Company Profile

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

Key Executives

Name Position
Carrie Eglinton Manner President, Chief Executive Officer & Director
Kenneth J. McGrath Chief Financial Officer
Amy Steigerwalt Senior Vice President of Human Resources
Anne Messing Chief Commercial Officer
David A. Rappaport Senior Vice President of Corporate Development, Strategy & Integration
Jason Michael Plagman Vice President of Investor Relations
Karen Davies Diagnostics R&D & Chief Technologist
Michael A. Pollner Senior VP, General Counsel & Corporate Secretary
Michele Anthony Senior Vice President, Chief Accounting Officer, Controller & Assistant Secretary
Rafal Iwasiow Sample Management Solutions R&D & Chief Scientist
Stefano Taucer General Counsel & Corporate Secretary
Zachary Wert Senior Vice President of Global Operations

Latest SEC Filings

Date Type Title
Aug 12, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 07, 2026 S-8 Filing
Aug 07, 2026 10-Q Quarterly Report
Aug 05, 2026 8-K Current Report
Jul 31, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Jun 30, 2026 4 Filing
Jun 11, 2026 8-K Current Report
Jun 05, 2026 4 Filing
Jun 05, 2026 4 Filing
Jun 05, 2026 4 Filing
View All SEC Filings
OraSure Technologies Inc.
OraSure Technologies Inc. logo
Country United States
IPO Date Nov 16, 1986
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 500
CEO Carrie Eglinton Manner

Contact Details

220 East First Street Bethlehem, Pennsylvania 18015 United States

Stock Details

Ticker Symbol OSUR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001116463
CUSIP Number 68554V108
ISIN Number US68554V1089
SIC Code 3841

© 2026 bestshares.com. All rights reserved.